PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19752719-5	2009	Simultaneous exposure to lapatinib and caelyx in SkBr3 cell line produced an additive cytotoxic effect with dephosphorylation of HER2 and EGFR, an upregulation of p21, and an induction of apoptosis through dephosphorylation of BAD and caspase cleavage.	liposomal doxorubicin	39-45	erb-b2 receptor tyrosine kinase 2	Homo sapiens	129-133	
19752719-8	2009	Our data indicate that lapatinib used in combination with caelyx is active in HER2-expressing cells, probably because of lapatinib-induced dephosphorylation of the HER2-EGFR pathway, and also in non-HER2-expressing cells, possibly because lapatinib blocks efflux pump activity, increasing the length of time of intracellular exposure to caelyx and thereby increasing its cytotoxic effect.	liposomal doxorubicin	58-64	erb-b2 receptor tyrosine kinase 2	Homo sapiens	78-82	
19752719-8	2009	Our data indicate that lapatinib used in combination with caelyx is active in HER2-expressing cells, probably because of lapatinib-induced dephosphorylation of the HER2-EGFR pathway, and also in non-HER2-expressing cells, possibly because lapatinib blocks efflux pump activity, increasing the length of time of intracellular exposure to caelyx and thereby increasing its cytotoxic effect.	liposomal doxorubicin	58-64	erb-b2 receptor tyrosine kinase 2	Homo sapiens	164-168	
19752719-8	2009	Our data indicate that lapatinib used in combination with caelyx is active in HER2-expressing cells, probably because of lapatinib-induced dephosphorylation of the HER2-EGFR pathway, and also in non-HER2-expressing cells, possibly because lapatinib blocks efflux pump activity, increasing the length of time of intracellular exposure to caelyx and thereby increasing its cytotoxic effect.	liposomal doxorubicin	58-64	erb-b2 receptor tyrosine kinase 2	Homo sapiens	164-168	
34826322-4	2021	The TsAb-Lipo-Dox exhibited specific targeting and enhanced cytotoxicity against mono- and co-cultured HER2+ breast cancer cells and FAP+ TAFs, compared to bi-specific antibody (BsAb) modified or unmodified Lipo-Dox.	liposomal doxorubicin	9-17	erb-b2 receptor tyrosine kinase 2	Homo sapiens	103-107	
34826322-2	2021	We developed an anti-HER2/anti-FAP/anti-mPEG tri-specific antibody (TsAb) for one-step conversion of mPEG-coated liposomal doxorubicin (Lipo-Dox) to immunoliposomes, which simultaneously target HER2+ breast cancer cells and FAP+ TAFs.	liposomal doxorubicin	136-144	erb-b2 receptor tyrosine kinase 2	Homo sapiens	21-25	
34826322-2	2021	We developed an anti-HER2/anti-FAP/anti-mPEG tri-specific antibody (TsAb) for one-step conversion of mPEG-coated liposomal doxorubicin (Lipo-Dox) to immunoliposomes, which simultaneously target HER2+ breast cancer cells and FAP+ TAFs.	liposomal doxorubicin	136-144	erb-b2 receptor tyrosine kinase 2	Homo sapiens	194-198	
31251311-1	2019	For those patients with HER2-overexpressing breast cancer, treatment with PEGylated liposomal doxorubicin (PLD) is inefficacious due to the intrinsic low sensitivity to doxorubicin.	liposomal doxorubicin	107-110	erb-b2 receptor tyrosine kinase 2	Homo sapiens	24-28